Loading
Alzheimer Disease / Disease Models, Animal / Alzheimer’s Disease · unknown
Channels · June 22, 2026
Early or partial results. Treat as a signal, not a conclusion.
This preclinical study in a mouse Alzheimer's disease model identifies mTORC2-mediated phosphorylation of Nav1.2 voltage-gated sodium channels as a molecular mechanism driving early hyperexcitability, a biomarker of early-stage AD. The findings position the mTORC2-Nav1.2 interaction as a potential therapeutic target for attenuating pathogenic hyperexcitability in early-stage Alzheimer's disease.
Preclinical mechanistic study. Murine Alzheimer's disease model, specifically neocortical pyramidal neurons. Intervention: Genetic deletion of mTOR complex 2 (mTORC2).
Hyperactive mTOR signaling stimulates Nav1.2 channel function through mTORC2 activity Augmented Nav1.2 channel function is selective among major brain Nav channel isoforms Neocortical pyramidal neurons in murine AD model display augmented Nav1.2 channel function and hyperexcitability requiring mTORC2 activity
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This mechanism provides a rationale for targeting the mTORC2-Nav1.2 pathway to modify hyperexcitability in early Alzheimer's disease, though clinical applicability and therapeutic feasibility remain to be established in human studies.
Mouse model identifies mTORC2-Nav1.2 mechanism underlying hyperexcitability in Alzheimer's disease, but lacks clinical translation or quantified intervention effect.
As stated by the source record.
This mechanism provides a rationale for targeting the mTORC2-Nav1.2 pathway to modify hyperexcitability in early Alzheimer's disease, though clinical applicability and therapeutic feasibility remain to be established in human studies.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Hyperexcitability is a biomarker of early-stage Alzheimer's Disease (AD) and hastens cognitive decline later in its course. Mechanistic target of rapamycin (mTOR) signaling contributes to the slope of this trajectory, as evidenced by early increased brain expression and the rescue of hyperexcitability by genetic deletion of mTOR complex 2 (mTORC2); however, a molecular mechanism directly linking mTOR signaling to membrane hyperexcitability in early-stage AD remains elusive. Here, we show that hyperactive mTOR signaling stimulates the voltage-gated Na+ channel 1.2 (Nav1.2), a previously identified downstream phosphorylation target of mTORC2 and a key regulator of membrane electrogenesis. Augmented Nav1.2 channel function induced by hyperactive mTOR signaling requires the action of mTORC2 and is selective among major brain Nav channel isoforms. In a murine AD model, neocortical pyramidal neurons display augmented Nav1.2 channel function and hyperexcitability through a mechanism that requires mTORC2 activity. These results highlight the mTORC2-Nav1.2 interaction as a therapeutic target for attenuating pathogenic hyperexcitability in early-stage AD.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.